{"id":4953,"date":"2025-10-30T11:58:41","date_gmt":"2025-10-30T08:58:41","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4953"},"modified":"2025-10-30T11:58:42","modified_gmt":"2025-10-30T08:58:42","slug":"hansa-imlifidase-reduce-anti-aav-antibodies-and-allow-administration-of-gene-therapy","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/hansa-imlifidase-reduce-anti-aav-antibodies-and-allow-administration-of-gene-therapy\/","title":{"rendered":"L'imlifidase de Hansa r\u00e9duit les anticorps anti-AAV et permet l'administration de la th\u00e9rapie g\u00e9nique"},"content":{"rendered":"

SRP-9001-104 dans la dystrophie musculaire de Duchenne (DMD) : Les principaux r\u00e9sultats ont \u00e9t\u00e9 rapport\u00e9s pour trois patients atteints de DMD trait\u00e9s par imlifidase avant l'administration d'ELEVIDYS de Sarepta dans l'essai.<\/p>\n\n\n\n

Deux essais de th\u00e9rapie g\u00e9nique, l'un sponsoris\u00e9 par Sarepta et l'autre par Genethon, confirment la capacit\u00e9 de l'imlifidase \u00e0 r\u00e9duire consid\u00e9rablement les anticorps anti-AAV afin de permettre l'administration de la th\u00e9rapie g\u00e9nique.<\/p>\n\n\n\n

Des taux \u00e9lev\u00e9s d'anticorps anti-AAV pourraient ne plus constituer un obstacle \u00e0 l'administration de la th\u00e9rapie g\u00e9nique.<\/h2>\n\n\n\n

Apr\u00e8s une seule dose d'imlifidase, les patients ont pr\u00e9sent\u00e9 une r\u00e9duction rapide des anticorps IgG, \u00e0 des niveaux inf\u00e9rieurs ou \u00e9gaux \u00e0 95% par rapport \u00e0 la valeur initiale. De plus, les anticorps anti-AAV pr\u00e9existants ont \u00e9t\u00e9 r\u00e9duits \u00e0 un titre inf\u00e9rieur \u00e0 1:400, permettant ainsi le traitement par ELEVIDYS. Aucun nouveau signal de s\u00e9curit\u00e9 n'a \u00e9t\u00e9 observ\u00e9 au cours de l'essai. Ces premi\u00e8res donn\u00e9es cliniques confirment la capacit\u00e9 de l'imlifidase \u00e0 r\u00e9duire significativement les anticorps anti-AAV, rendant possible l'administration de th\u00e9rapies g\u00e9niques. En savoir plus sur l'imlifidase<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"

SRP-9001-104 in Duchenne muscular dystrophy (DMD): Topline results were reported for three patients with DMD treated with imlifidase prior to administration of Sarepta’s ELEVIDYS in the trial. Two gene therapy trials, one sponsored by Sarepta and the other sponsored by Genethon, support the ability of imlifidase to substantially reduce anti-AAV antibodies to allow administration of […]<\/p>\n","protected":false},"author":1,"featured_media":4954,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[368,448,61,401],"class_list":["post-4953","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-aav-based-gene-therapy","tag-anti-aav","tag-gene-therapy","tag-hansa-biopharma"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/4953","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=4953"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/4953\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/4954"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=4953"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=4953"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=4953"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}